Elevate your local knowledge
Sign up for the iNFOnews newsletter today!
LAVAL, Que. – Bausch Health Companies Inc. has been selected as the winning bidder to acquire certain assets of Synergy Pharmaceuticals Inc. for about $195 million plus certain liabilities.
The Quebec-headquartered pharmaceutical company formerly called Valeant Inc. had been the “stalking horse” bidder in a court-supervised auction and sale process.
Synergy, a U.S. maker of gastrointestinal therapies, filed for bankruptcy in December under Chapter 11.
A hearing to approve the sale is scheduled for Friday.
Bausch says the acquisition will enhance its Salix Pharmaceuticals business since Synergy’s Trulance product would “strategically enhance” its product for gastrointestinal problems, Xifaxan, and its sales footprint.
The deal is the company’s first acquisition in more than three years since Valeant purchased Sprout Pharmaceuticals, the maker of a female sexual dysfunction drug, for about US$1 billion, before selling it for next to nothing a couple of years later.
Companies in this story: (TSX:BHC).
News from © iNFOnews.ca, . All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Want to share your thoughts, add context, or connect with others in your community?
You must be logged in to post a comment.